Clinical Trial Update: Dalbavancin Outpatient Pilot [Phase 4]

View source ↗

Summary

A Phase 4 outpatient pilot trial of dalbavancin was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gram-positive Bacterial Infections
• Soft Tissue Infections

Drugs mentioned

• Dalbavancin (dalbavancin)

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Gram-Positive Bacterial Infections, Soft Tissue Infections | Phase 4 | Status: WITHDRAWN